Naoki Takamatsu

Naoki Takamatsu

Auto-generated profile, based on publicly available information

Naoki Takamatsu

Department of Neuropsychiatry, Graduate School of Medicine, The University of Tokyo, Tokyo, Japan

Research Focus & Metrics

Academic Career Length

3Years (2024-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
10 October 2025 in BMC Infectious Diseases
Verified
Journal Article
Open access
PDF file
NTNaoki Takamatsu
Naoki Takamatsu
HKHironori Kuga
Hironori Kuga
Long COVID presents a spectrum of persistent symptoms that substantially overlap with myalgic encephalomyelitis/chronic fatigue syndrome (ME/CFS), including debilitating fatigue, post-exertional malaise, cognitive dysfunction, and neuropsychiatric manifestations. Despite growing evidence of shared pathophysiological mechanisms, neither condition has established diagnostic biomarkers or disease-modifying treatments. Cognitive behavior therapy (CBT), when appropriately implemented, may serve as one component of comprehensive care. This review examines the neuropsychiatric manifestations, management principles, and implementation considerations for CBT in long COVID, drawing insights from ME/CFS experience. Our analyses revealed substantial overlap between patients with long COVID and ME/CFS including immune dysregulation, neuroinflammation, and metabolic dysfunction while identifying distinct features in disease trajectories. Evidence suggests ME/CFS may represent a severe phenotype in a subset of patients with long COVID. Management principles applicable to both conditions include patient validation, comprehensive needs assessment, individualized energy management, symptom-specific interventions, and comorbidity management. Current clinical trials demonstrate methodological evolution in CBT implementation, from traditional protocols to digital platforms. Moderate-certainty evidence indicates CBT may reduce fatigue and improve cognitive function in long COVID. However, substantial heterogeneity exists in both intervention characteristics and condition definitions. Implementation success requires provider competency, terminological precision, and individualized approaches that respect energy limitations. Careful monitoring for post-exertional symptom exacerbation is essential. We emphasize that these approaches do not imply these conditions are primarily psychological. Our review synthesizes current evidence on CBT in long COVID management, considering lessons from ME/CFS. Substantial challenges remain in standardizing terminology, strengthening trial methodology, and determining optimal implementation strategies. Future research should incorporate objective outcome measures alongside subjective reports, while clinical practice should consider how cognitive-behavioral approaches might contribute to comprehensive care plans tailored to individual patient needs. This approach recognizes that addressing both physical and psychological dimensions of these conditions may enhance treatment outcomes, while acknowledging the individualized nature of patient responses to different therapeutic elements.

27 February 2026 in Neuropsychopharmacology Reports
Verified
Journal Article
Open access
PDF file
NTNaoki Takamatsu
Naoki Takamatsu
HKHiroki Kimura
Hiroki Kimura
MOMari S. Oba
Mari S. Oba
HCHiroyuki Chiba
Hiroyuki Chiba
IUIkue Umemoto
Ikue Umemoto
HKHironori Kuga
Hironori Kuga
Aim: COVID‐19 has been associated with dysregulated immune responses, with increasing evidence indicating sustained inflammasome activation and subsequent pro‐inflammatory cytokine production. This study aimed to characterize the temporal profile of inflammatory markers, particularly interleukin (IL)‐1β, in post‐COVID‐19 patients compared with pre‐pandemic healthy controls, using data from the Psychiatric Symptoms for COVID‐19 Registry Japan (PSCORE‐J). Methods: Blood samples were analyzed from 119 post‐COVID‐19 patients (median age 45 years) recruited during 2023 and 374 pre‐pandemic healthy controls (median age 65 years). For post‐COVID‐19 patients, samples were collected at baseline, 3 months, and 9 months. Multiple inflammatory markers were assessed, including IL‐1β, IL‐6, IL‐8, IL‐10, IL‐12, TNF‐α, IFN‐γ, IFN‐β, IP‐10, ACE2, and eotaxin. Age‐ and sex‐adjusted analyses were performed on log‐transformed IL‐1β levels. Results: IL‐1β levels were significantly elevated in post‐COVID‐19 patients compared with healthy controls across all age groups (under 30s: 0.69 ± 0.33 vs. 0.25 ± 0.03; 30s: 0.70 ± 0.63 vs. 0.26 ± 0.09; 40s: 0.84 ± 0.76 vs. 0.30 ± 0.23; 50s: 0.67 ± 0.65 vs. 0.26 ± 0.10; 60 or over: 0.54 ± 0.30 vs. 0.26 ± 0.23 pg/mL). This elevation was sustained throughout the 9‐month follow‐up (baseline: 0.500 [0.33–0.890]; 3 months: 0.630 [0.28–1.290]; 9 months: 0.54 [0.29–0.96] pg/mL) compared with controls (0.24 [0.21–0.27] pg/mL). Other inflammatory markers showed either no significant differences or were paradoxically lower in patients. Conclusion: SARS‐CoV‐2 infection is associated with persistent elevation of IL‐1β levels that remains stable over a 9‐month period, suggesting sustained inflammasome activation. These findings provide novel insight into post‐COVID‐19 inflammatory processes and may have important implications for understanding both acute and chronic manifestations of the disease. Trial Registration: Japan Registry of Clinical Trials: jRCT1030220711

1 July 2024 in Psychiatry and Clinical Neurosciences Reports
Verified
Journal Article
Open access
SSSo Sugita
So Sugita
KHKotone Hata
Kotone Hata
KKKrandhasi Kodaiarasu
Krandhasi Kodaiarasu
NTNaoki Takamatsu
Naoki Takamatsu
KKKentaro Kimura
Kentaro Kimura
HKHironori Kuga
Hironori Kuga
The aim of this scoping review was to synthesize published studies and ongoing clinical trials of psychological interventions for mental health problems associated with COVID‐19 infection. The study protocol was developed according to the Preferred Reporting Items for Systematic Reviews and Meta‐Analyses (PRISMA) Extension for Scoping Reviews. We conducted systematic searches for studies published or registered between January 2020 and October 2022 using eight scientific databases and clinical trial registries, which identified 40 complete published studies and 53 ongoing clinical trials. We found that most studies were randomized controlled trials (74%) while the remaining used study designs of lower methodological quality. Most studies investigated interventions for acute COVID‐19 patients (74%) and others explored post‐COVID conditions (PCC) or recovered patients. Cognitive and behavioral therapies were the main intervention approaches (31%), followed by multidisciplinary programs (21%) and mindfulness (17%). The most frequently evaluated outcomes were anxiety (33%), depression (26%), quality of life (13%), and insomnia (10%). No studies on youths, older people, or marginalized communities were found. These findings summarize the burgeoning research on a range of psychological interventions for individuals infected with COVID‐19. However, the field is in its infancy and further research to develop an evidence base for targeted care is necessary. The gaps identified in the current study also highlight the need for more research on youths, older people, and members of marginalized communities, and PCC patients. It is important to ascertain interventions and delivery strategies that are not only effective and affordable but also allow high scalability and accessibility.

2 December 2024 in Psychiatry and Clinical Neurosciences Reports
Verified
Journal Article
Open access
NTNaoki Takamatsu
Naoki Takamatsu
MNMisuzu Nakashima
Misuzu Nakashima
KMKei Matsuura
Kei Matsuura
IUIkue Umemoto
Ikue Umemoto
MIMasaya Ito
Masaya Ito
HKHironori Kuga
Hironori Kuga
Background: Attention‐deficit/hyperactivity disorder (ADHD) symptoms, including executive function, emotional regulation, and motivation, can persist into adulthood and are often associated with mental illnesses. Cognitive behavioral therapy (CBT) may help ADHD adults in Japan, but the lack of studies and the variability in group CBT approaches make its effects unclear. Japan lacks unified CBT programs and adult ADHD guidelines, making it difficult to implement international individual CBT recommendations due to cultural differences. This study will assess the feasibility of a novel CBT program for Japanese adult ADHD patients.Methods: This feasibility study will be open, nonrandomized, single‐arm, multicenter study. Twelve ADHD patients aged 20–65 years who are currently receiving treatment will be included based on Conners' Adult ADHD Rating Scale (CAARS) clinical severity threshold. An intervention phase of 12–16 weeks and a 12‐week follow‐up will total 24–28 weeks for all participants. The intervention will use a new CBT program tailored to individual assessments.Results: The primary objective is to determine feasibility using dropout rates, adverse events, and CAARS score changes between Weeks 1 and 16. The secondary outcomes will assess long‐term effects of treatment beyond the intervention period and provide descriptive statistics on sex, depression, quality of life, and autistic scores in relation to the intervention outcomes. The full analysis set and per protocol set will be used for statistical analysis.Conclusions: This study is essential for the development of CBT interventions in accordance with Japan's healthcare system that are tailored to the unique needs of its population.

12 January 2026 in Psychiatry and Clinical Neurosciences
Verified
Journal Article
Closed access
NTNaoki Takamatsu
Naoki Takamatsu
EZEkachaeryanti Zain
Ekachaeryanti Zain
KLKa Ying Heidi Lo
Ka Ying Heidi Lo
PPPolona Rus Prelog
Polona Rus Prelog
RKRoxanne C. Keynejad
Roxanne C. Keynejad
TSTomohiro SHIRASAKA
Tomohiro SHIRASAKA

29 July 2026 in Research Square
Verified
Preprint
Open access
PDF file
NTNaoki Takamatsu
Naoki Takamatsu
IUIssei Ueda
Issei Ueda
YSYoshito Saito
Yoshito Saito
YTYusuke Takahashi
Yusuke Takahashi
TETakahide Etani
Takahide Etani
SNShinichiro Nakajima
Shinichiro Nakajima
Case-control comparisons of group means in psychiatric and neurological neuroimaging cannot quantify individual deviation from population norms. Normative modeling, akin to pediatric growth charts, locates individuals within a reference distribution to yield individualized deviation scores. We reviewed 122 normative-modeling studies across neuroimaging and neurophysiological measures. Structural MRI accounted for 71% of studies. Statistical methodology has shifted from Gaussian process regression toward Bayesian and distributional approaches. Reference cohort sizes spanned 51–77,157 (median 642). The 15 cohorts of 10,000 or more drew most often on UK Biobank (73%), whether directly or within multi-site aggregations, and 20% provided self-reported race or ethnicity. External validation was reported in 8% of applicable studies, and a single model accounted for 38% of pre-trained applications. Methodological refinement has outpaced the empirical foundations and reporting transparency required for clinical translation. To address this, we introduce NORMA, an 18-item reporting checklist for model construction, validation, and clinical application.